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Background/aim: Sjögren’s syndrome (SS) is an autoimmune disease and its pathogenesis is still not completely clear. The wingless
(Wnt)/β-catenin pathway has recently been shown to play an important role in inflammation. This study aims to determine the serum
and saliva levels of Dickkopf (DKK)1 and sclerostin and to evaluate Wnt-1 and Wnt-3a expression in the salivary gland in patients with
primary SS.
Materials and methods: This study included 30 patients diagnosed with SS, 30 patients diagnosed with systemic lupus erythematosus
(SLE), and 29 healthy controls. Serum and saliva levels of DKK1 and sclerostin were measured and the expressions of Wnt1 and Wnt3a
in the salivary gland were measured immunohistochemically.
Results: Serum DKK1 and sclerostin levels were lower in the SS and SLE groups compared to the control group (both p < 0.001). Saliva
DKK1 levels were higher in the SS group compared to the control and SLE groups (p = 0.004 and p = 0.009, respectively). Wnt1 and
Wnt3a expression were found in salivary gland tissue samples in 71.4% of primary SS patients and relatively frequent than control group.
Conclusions: Serum DKK1 and sclerostin levels in primary SS and SLE were decreased. Moreover, levels of Wnt1 and Wnt3a expression
in the salivary gland were also elevated in primary SS. Therefore, it can be concluded that the Wnt/β-catenin pathway activities may be
altered in case of glandular inflammation.
Key words: Sjögren syndrome, wingless, sclerostin, dickkopf -1

1. Introduction
Sjögren’s syndrome (SS) is a systemic autoimmune
disease that is prevalent in women [1,2]. Its pathogenesis
is not completely clear; however, genetic disposition,
viral stimulation, hormonal factors, and natural and
acquired immunity have been implicated [3–6]. The chief
symptoms of the disease include dryness in the mouth and
eyes, fatigue, and joint pain due to exocrinopathy. These
symptoms, particularly fatigue, decrease the patient’s
life quality and result in an impairment of cognitive
capacity [7–9]. Currently, there is no completely effective
treatment for these symptoms [10]. Thus, determining the
pathogenesis of this disease is important. Accordingly,
studies are being conducted to identify the pathologic
pathways.

The wingless (Wnt) signaling pathway plays an
important role in the development of the immune system,
at the organogenesis stage, and in the regulation of various
biological events such as the proliferation and differentiation
of cells [11,12]. The Wnt/β-catenin signaling pathway
is activated by proteins such as low-density lipoprotein
receptor-related protein (LRP) 5, LRP6 and frizzled, and
inhibited by extracellular proteins such as sclerostin and
Dickkopf (DKK) 1 [12–16]. Studies have been conducted on
the Wnt pathway in relation to various rheumatic diseases
such as rheumatoid arthritis (RA), spondyloarthritis, and
systemic lupus erythematosus (SLE); and this pathway was
shown to be linked to the pathogenesis [17,18].
The present study aims to evaluate the serum
and saliva levels of sclerostin and DKK1, and to
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immunohistochemically evaluate the levels of Wnt1 and
Wnt3a expression in the salivary gland, in patients with
primary SS. Moreover, the relationship between these
parameters and clinical activity were also determined.
2. Materials and methods
2.1. Study subjects
The study was carried out by the departments of
rheumatology at Fırat University. Ethical committee
approval was obtained from Fırat University clinical
research ethics committee. We conducted our study
in accordance with the approved guidelines of ethical
principles for medical research involving human
subjects. Written informed consent was provided from all
participants. This study included 30 primary SS patients,
30 patients diagnosed with SLE (as a patient control
group), and 29 healthy controls.
The SS and SLE patient groups were composed of
patients who applied to the rheumatology outpatient
clinic, met the respective diagnostic criteria [19,20], and
agreed to participate in the study. The healthy control
group was composed of volunteers who applied to the
rheumatology outpatient clinic but did not have rheumatic
inflammatory pathology according to the evaluations.
Individuals younger than 18 years and older than 65 years;
pregnant women; breastfeeding women; and patients with
active infections, poorly controlled diabetes, heart failure,
and malignant diseases were excluded from the study.
In addition, archived salivary gland tissue samples
of 14 patients, diagnosed with SS and included in the
study, and of 12 patients who had provided salivary
gland tissue specimens for a preliminary diagnosis of
SS but were not diagnosed with SS (pathological control
group) were included in the study to be evaluated
immunohistochemically for Wnt1 and Wnt3 expression
levels. Therefore, the time to harvest salivary gland tissue
samples was different from the time periods from saliva
and serum sample harvesting.
2.2. Clinical evaluation
The patients were evaluated with regards to the parameters
of disease activity used in the follow-up of SS and SLE.
Disease activity was determined using ESSDAI (EULAR
SS disease activity index) and ESSPRI (EULAR SS patient
reported index) in SS patients [21], and using SLEDAI
(systemic lupus erythematosus disease activity index) in
SLE patients [22].
2.3. Laboratory evaluation
The results of the routine tests (fasting blood sugar,
creatinine, ALT, blood count, erythrocyte sedimentation
rate [ESR], and C-reactive protein [CRP]) were recorded in
the patient and the control groups. Additionally, for the SS
group, results indicating ANA, anti-Ro, anti-La; and for the
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SLE group ANA, anti-dsDNA, anti-Sm, C3, and spot urine
protein were recorded from the patient files. In addition
to these routine tests, 5 mL blood and 2 mL saliva samples
were collected from all participants after overnight fasting.
Blood samples were centrifuged at 3000 rpm for 5 min,
and 2 mL of serum was separated. The obtained serum and
saliva samples were stored at –20 °C until the day of the
analysis. At the end of the study, the stored samples were
assessed to determine serum and saliva levels of sclerostin
and DKK1 with the ELISA method, using an appropriate
commercial kit (YH Biosearch, Pudong District, China).
2.4. Histopathological evaluation
Salivary gland tissue samples of 14 SS patients that had
been collected for diagnostic purposes, and archived tissue
samples of 12 patients who had provided minor salivary
gland tissue samples due to a preliminary diagnosis of
SS but were not diagnosed with SS (pathology control
group) were included in the study. Tissue specimens were
paraffin embedded. Formalin-fixed paraffin-embedded
tissue sections that were cut 3-μm thick were placed onto
positively charged glass slides (Isotherm, Objektträger,
Braunschweig, Germany). Immunohistochemical (IHC)
staining was performed using tissue sections to determine
Wnt1 and Wnt3a expression. The following antibodies
were used for immunohistochemistry: Wnt1 (Mouse Wnt1
primary antibody (10C8), NBP1-51575, Novus biologicals,
USA) and Wnt3a (Mouse Wnt3a primary antibody,
NBP1-74183, Novus biologicals, USA). IHC staining of
tissue sections were used the Ventana BenchMark Ultra
Autostainer (Ventana, Tuscon, AZ-85755, USA) and the
UltraView Univerversal DAB kit (Ventana, Tuscon, AZ85755, USA), following the manufacturer’s instructions.
Tissue sections were imaged with an Olympus B×51
upright light microscope (Olympus America, Center
Valley, PA, USA) and images captured in digital color
camera (DP71, Olympus).
In the evaluations, the criteria for positivity was
defined as cytoplasmic staining in the ducts. The findings
were graded based on staining intensity as follows; [23]
-: no staining,
+: mild staining,
++: moderate staining,
+++: strong staining.
2.5. Statistical analysis
The continuous data obtained in the study were presented
as mean ± standard deviation, while nonparametric
data without normal distribution were expressed as
median (minimum-maximum). Statistical analyses were
conducted using the IBM-SPSS, v: 22.0 software (IBM
Corp., Armonk, NY, USA). The Chi-square test was used
for categorical data. Normal distributions were tested
with the Kolmogorov–Smirnov test. The significant
difference among groups was determined by the Kruskal–
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Wallis variance analysis and the Mann–Whitney U test
for dual comparisons in the nonnormal distributed and
nonparametric data. One-way ANOVA and the student’s
t-test for dual comparisons were performed parametric
data with normal distribution. Bonferroni correction was
applied since there were three study groups. Analysis of
covariance (ANCOVA) was also used to adjust variables
for age and sex. P-values < 0.05 were considered significant.
3. Results
3.1. Baseline characteristics
The demographic and clinical data of the study groups
were presented in the Table 1. The median (min-max) age
was determined as 51 (36–65) years for the SS group, as 37
(22–50) years for the SLE group, and 29 (23–57) years for
the healthy control group. The percentage of females in the
healthy control, SLE, and SS groups were determined as
51.7%, 80%, and 100%, respectively. ANCOVA was used
to adjust variables for age and sex, since the differences
between the groups in terms of age and sex were statistically
significant (both p < 0.05). The median (min-max) disease
duration was 1.7 (0–11) years for SS patients and 1.5 (0–
13) years for the SLE group. The groups did not differ the
disease durations (p > 0.05).
3.2. Basic laboratory tests
Hemoglobin levels were significantly lower in the SS and
SLE groups compared to the healthy control group (p =
0.004 and p < 0.001, respectively). However, there were no
statistically significant differences with regard to leukocyte,

platelet, and CRP levels. ESR was higher in the SLE and SS
groups compared to the control group (p < 0.001 for both).
3.3. Disease activity score of SLE and SS patients
Systemic lupus erythematosus patients showed a median
SLEDAI score of 10 (0–29), and SS patients showed a
median ESSDAI score of 1 (0–3). ANA positivity was 96%
in the SLE group and 83.3% in the SS group.
3.4. The sclerostin and DKK1 levels of the patient and
healthy control groups
The SS group demonstrated lower serum DKK1 and
sclerostin levels compared to the control group (both p <
0.001), even after adjustment for age and sex by ANCOVA
analysis. However, saliva levels of DKK1 and sclerostin
were comparable across the SS and healthy control groups
(p > 0.05). Serum DKK1 and sclerostin levels were lower
in SLE patients compared to healthy controls (p < 0.001
for both). However, the SLE group did not differ from the
control group in terms of saliva DKK1 and sclerostin levels.
In addition, serum and saliva levels of DKK1 were higher
in patients diagnosed with SS compared to the SLE group
(p = 0.046 and p = 0.009, respectively). However, the SS and
SLE groups were not significantly different with regards to
serum and saliva levels of sclerostin.
A positive correlation was determined between serum
DKK1 levels and serum sclerostin levels in the healthy
control, SLE, and SS groups (respectively; r = 0.829, p <
0.001; r = 0.783, p < 0.001; and r = 0.677, p < 0.001). Serum
and saliva levels of sclerostin and DKK1 were not correlated
with ESSDAI and SLEDAI in these groups (p > 0.05).

Table 1. Demographic and clinical data of the study groups.
Data×

HC
(n = 29)

SLE
(n = 30)

SS
(n = 30)

P1*

P2*

P3*

Age, years

29 (23–57)

37 (22–50)

51 (36–65)

0.068

<0.001

0.001

Disease duration, years

-

1.7 (0–11)

1.5 (0–13)

-

-

0.738

Female, %

51.7

80

100

0.029

< 0.001

0.023

Hemoglobin, g/dL

14.7 ± 1.2

12.4 ± 2.1

13.3 ± 1.5

< 0.001

0.004

0.104

WBC, 10 /µL

7.2 ± 1.9

6.2 ± 2.4

5.9 ± 1.8

0.140

0.069

0.907

ESR, mm/h

5 (1–39)

18.5 (3–66)

12 (5–71)

<0.0001

<0.0001

0.361

CRP, mg/dL

3.4 (3–16.8)

3.4 (1.9–14.6)

3.4 (3.2–70)

0.612

0.368

0.778

Serum DKK1, ng/mL

52.9 (24.1–74.5)

26.5 (2.1–63.2)

33.9 (20.6–59)

< 0.001

< 0.001

0.046

Saliva DKK1, ng/mL

30.6 ± 5.9

31.1 ± 6.9

36.3 ± 6.9

0.944

0.004

0.009

Serum sclerostin, ng/mL

15.5 (3.4–18.3)

4.6 (2.1–18.1)

4.5 (2–18.6)

< 0.001

< 0.001

0.984

Saliva sclerostin, ng/mL

16.1 ± 3.4

15.7 ± 2.5

15.6 ± 3.7

0.877

0.838

0.996

3

HC: healthy control, SS: Sjögren’s syndrome, WBC: white blood cell, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein,
DKK1: Dickkopf-related protein 1.
×
Data were expressed as mean ± SD and median (min-max) for parametric and nonparametric values, respectively.
*Mann–Whitney U test was applied for dual comparisons (P1: SLE vs. HC, P2: SS vs. HC, P3: SS vs. SLE).
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3.5. Wnt1 and Wnt3a expression were increased in the
salivary gland of the patients with SS
Wnt1 and Wnt3a positivity were higher in the salivary
gland biopsy samples of patients diagnosed with SS
compared to the control group (Figures 1a, 1b for Wnt1;
Figures 2a, 2b for Wnt3a). However, this difference was not
statistically significant (Table 2).
SS patients with Wnt1- and Wnt3a-positive salivary
glands and those with Wnt1- and Wnt3a-negative salivary
glands did not have significantly different serum and saliva
levels of DKK1 and sclerostin (for each p > 0.05). Similarly,
Wnt1- and Wnt3a-positive SS patients and Wnt1- and
Wnt3a-negative SS patients were not significantly different
with regard to ANA, anti-Ro, and anti-La antibody
positivity (for each p > 0.05) (Table 3).

4. Discussion
The aim of this study was to determine the activity of
Wnt/β-catenin signaling pathway in primary SS. For this
purpose, serum and salivary sclerostin and DKK1 levels
and Wnt1 and Wnt3a immunohistochemical expressions
in salivary gland tissue were evaluated.
SS is a chronic, autoimmune disease that mainly affects
the tear and salivary glands. Lymphocyte infiltration and
dysfunction of the exocrine glands results in dry mouth and
eyes [24]. Hereditary and environmental factors have been
implicated in the pathogenesis. One of the most important
theories in the pathogenesis is that the SS is a process that
starts with epithelitis and then continues with lymphocyte
infiltration. Therefore, the disease is considered by some
researchers as autoimmune epithelitis [25]. Moreover,

Figure 1. Immunohistochemical Wnt1 expression in the salivary gland. (a) Strong nuclear and cytoplasmic Wnt1 positivity in the ducts
and acini in controls (×400), (b) Mild nuclear and cytoplasmic Wnt1 positivity in the ducts and acini in SS patients (×400).

Figure 2. Immunohistochemical Wnt3a expression in the salivary gland. (a) Mild nuclear and cytoplasmic Wnt3a positivity in the ducts
and acini in controls (×400), (b) Strong nuclear and cytoplasmic Wnt3a positivity in the ducts and acini in SS patients (×400).
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Table 2. Wnt1 and Wnt3a expressions in the salivary glands of patients with primary SS.
Control

Sjögren’s Syndrome

P*

Wnt1 positive patients, %

46.2

71.4

0.182

Mild, %

7.7

42.9

Moderate, %

15.4

14.3

Strong, %

23.1

14.3

Wnt3a positive patients, %

53.8

71.4

Mild, %

30.8

7.1

Moderate, %

15.4

14.3

Strong, %

7.7

50

0.345

*P-values of Chi-square test.
Table 3. Differences between Wnt1- and Wnt3a-positive and Wnt1- and Wnt3a-negative patients with primary SS.
Wnt1

Wnt3a

Data×

Negative

Positive

P*

Negative

Positive

P*

Anti-Ro titre, IU/L

131.2 ± 79.9

80.4 ± 95

0.1

98.2 ± 96.6

93.6 ± 2

0.7

Anti-La titre, IU/L

6.5 ± 2

76.7 ± 107.8

0.7

112.2 ± 134.3

32.6 ± 68.8

0.3

Serum DKK1, ng/mL

28.6 ± 5.8

36.9 ± 9

0.06

31.9 ± 4.3

35.6 ± 10.2

0.6

Saliva DKK1, ng/mL

38 ± 10.5

35.8 ± 7.2

0.8

37.9 ± 9.5

35.8 ± 7.7

0.6

Serum sclerostin, ng/mL

4.5 ± 2.5

5.2 ± 4.8

1

3.8 ± 1.1

5.5 ± 4.9

0.6

Saliva sclerostin, ng/mL

14.7 ± 2

14.2 ± 4.9

0.6

15.5 ± 1.7

13.9 ± 4.8

0.3

DKK1: Dickkopf-related protein 1.
×
Data were expressed as mean ± SD.
*P values of Mann–Whitney U test.

recent data show that salivary gland epithelial cells play an
active role in initiating an inflammatory and autoimmune
response [26].
Wnt/β - catenin signaling pathway plays an important
role in embryonic development, tissue homeostasis,
cellular proliferation, and also the regulation of the
immune system such as T, B and dendritic cells [27,28].
Genes associated with this pathway have been expressed
in a wide variety of cell types and tissues such as
adipocytes, osteoblasts, platelets, lymph glands, adrenal
glands, thyroid, pituitary, and salivary glands [29,30].
Wnt/β-catenin signaling pathway is known to play a role
in the pathogenesis of cancer and autoimmune diseases
[28,31–34]. In this respect, there are a number of studies
investigating biomarker in these diseases [35,36]. Wnt/βcatenin signaling pathway is an important regulatory
pathway in bone formation and destruction [37,38].
The blocking DKK1, which is an inhibitor of Wnt/βcatenin signaling pathway, decreased osteoclastic activity
and decreased bone erosion in RA patients [39]. It has also

been found that DKK1 levels increased in RA patients and
correlated with bone erosion [37]. Wehmeyer et al. [40]
have found that the sclerostin levels in the synovium of RA
are significantly higher than in patients with osteoarthritis.
In a subsequent study [41], it has been observed that
the level of DKK1 is higher in patients with RA and
glucocorticoid treatment decreases serum DKK1 level.
In our study, it is observed that serum DKK1 and
sclerostin levels are decreased in patients with primary
SS. There are controversial results in terms of DKK1 and
sclerostin levels in inflammatory diseases. Contrary to
the articles documenting increased serum DKK1 and
sclerostin levels in RA [40,41], Zhang et al. [42] have
reported that serum DKK1 level in patients with RA is
similar in healthy subjects. There are two controversial
study reporting increased [42] and decreased [43] serum
DKK1 levels in patients with ankylosing spondylitis.
Dovjak et al. [44] have found that DKK1 levels are
correlated with age and the presence of osteoporosis.
Furthermore, serum DKK1 level is higher in males. Gifre
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et al. [41] have documented that treatment alters serum
DKK1 levels. Therefore, it can be speculated that the
differences on demographical data, clinical manifestations,
and treatment modalities of the mentioned studies are
the potential reasons of controversial results of DKK1 in
inflammatory diseases.
In our study, it is documented that serum the level of
DKK1, an inhibitor of Wnt signaling pathway is decreased,
while glandular tissue Wnt1 and Wnt3a expressions
are relatively higher, in patients with primary SS. Wnt
signaling pathways are an important regulator in salivary
gland organogenesis. Wnt/β-catenin signaling plays a role
in both mesenchymal and ductal maturation of salivary
glands. On the other hand, the Wnt/β-catenin signal and
the noncanonical Wnt pathway work together to regulate
maturation in the morphogenesis stage [45,46]. However,
the Wn/β-catenin signal is significantly activated in the
channel epithelium during functional regeneration in the
adult salivary gland [46]. Fernandez-Torres et al. [47] have
found that gene polymorphisms such as LRP5, FRZB,
and ADIPOQ associated with Wnt/β-catenin signaling
pathway lead to increased risk of primary SS.

The present study has few limitations. The sample size
was not calculated before enrolling study participants.
Age and sex were not matched; however, adjustment for
age and sex by ANCOVA was performed during statistical
analysis. Moreover, salivary gland tissue and serum
samples were not harvested same time.
In present study, Wnt1 and Wnt3a expression are
found in salivary gland tissue samples in 71.4% of primary
SS patients. High salivary DKK1 levels in primary SS
group can be explained by glandular inflammation and
damage. According to the best of our knowledge, the
present study is the first to evaluate the efficacy of Wnt/βcatenin pathway in primary SS. In conclusion, in present
study, serum levels of DKK1 and sclerostin, Wnt/β-catenin
signaling pathway inhibitors, are decreased and Wnt1 and
Wnt3a are accumulated in the glandular tissue in primary
SS patients. These results indicate that Wnt/β-catenin
signaling pathway is affected in primary SS.
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